The impact of polygenic risk for alzheimer’s disease on neurotransmitter-related grey matter atrophy in the alzheimer continuum
Riccardo Manca, Micaela Mitolo, Maria Giulia Bacalini, Sabina Capellari, Annalena Venneri. Neurological Sciences, 2025-08-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Alzheimer’s disease (AD) pathology has been recently shown to accumulate in multiple brainstem nuclei in pre-cortical disease stages. However, the impact of neurotransmission alterations on brain atrophy and their genetic correlates in AD remain unexplored. This study investigated (1) associations between grey matter (GM) loss and uptake values of PET/SPECT ligands tracing concentration of multiple neurotransmitter receptors/transporters and pathways; (2) the impact of AD polygenic risk scores (AD-PRSs) on such associations along the AD continuum. T1-weighted MRI scans, genetic and clinical data were selected for 800 ADNI participants: 203 cognitively unimpaired older adults (CU), 442 with mild cognitive impairment (MCI) and 155 with AD. JuSpace was used to calculate correlations between GM volume (GMV) and the concentration of several neurotransmitters. Two PRSs, with (AD-PRS) and without APOE (AD-PRSnoAPOE), were investigated as predictors of the strength of correlation between GMV and neurotransmitters in general linear models. In both patient groups, atrophy was negatively associated with serotoninergic and dopaminergic receptors/transporters. In the whole sample, both PRSs were associated with the strength of correlation between GMV and different serotonin receptors and fluorodopa uptake. The pattern of associations was replicated in participants with evidence of amyloid pathology. GM loss in AD may be particularly affected by the alterations in serotoninergic and in presynaptic dopaminergic activity that are known to influence functioning of medio-temporal and frontal cortices. Such alterations appear to be driven by higher AD-PRS values. Investigating further neurotransmitter-related neural alterations may help clarifying neuropathological changes in pre-clinical AD and response to treatments.
What this study adds
Evidence grade: Low
In ADNI participants, brain atrophy was negatively associated with serotoninergic and dopaminergic receptors/transporters, and AD polygenic risk scores were associated with the strength of these correlations. This explores genetic and neurotransmitter links to atrophy, not any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Manca, R., Mitolo, M., Bacalini, M. G., Capellari, S., & Venneri, A. (2025). The impact of polygenic risk for alzheimer’s disease on neurotransmitter-related grey matter atrophy in the alzheimer continuum. Neurological Sciences. https://doi.org/10.1007/s10072-025-08393-3
Vancouver
Manca R, Mitolo M, Bacalini MG, Capellari S, Venneri A. The impact of polygenic risk for alzheimer’s disease on neurotransmitter-related grey matter atrophy in the alzheimer continuum. Neurological Sciences. 2025. doi:10.1007/s10072-025-08393-3. PMID: 40851051.
BibTeX
@article{manca2025-40851051,
author = {Manca, Riccardo and Mitolo, Micaela and Bacalini, Maria Giulia and Capellari, Sabina and Venneri, Annalena},
title = {{The impact of polygenic risk for alzheimer’s disease on neurotransmitter-related grey matter atrophy in the alzheimer continuum}},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-025-08393-3},
pmid = {40851051},
url = {https://doi.org/10.1007/s10072-025-08393-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In both patient groups, atrophy was negatively associated with serotoninergic and dopaminergic receptors/transporters.
- In the whole sample, both PRSs were associated with the strength of correlation between GMV and different serotonin receptors and fluorodopa uptake.
Why it matters
In ADNI participants, brain atrophy was negatively associated with serotoninergic and dopaminergic receptors/transporters, and AD polygenic risk scores were associated with the strength of these correlations. This explores genetic and neurotransmitter links to atrophy, not any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurological Sciences) |
| Journal's citation record | 1 / 4 | Neurological Sciences: journal h-index 113 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Annalena Venneri: h-index 58 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Bologna: institution h-index 989 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40851051) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s10072-025-08393-3
- PubMed: 40851051
- Original source →
- Free full text: Neurological Sciences →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.